Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles

Prostate cancer cells frequently overexpress the gastrin-releasing peptide receptor, and various strategies have been applied in preclinical settings to target this receptor for the specific delivery of anticancer compounds. Recently, elastin-like polypeptide (ELP)-based self-assembling micelles with tethered GRP on the surface have been suggested to actively target prostate cancer cells. Poorly soluble chemotherapeutics such as docetaxel (DTX) can be loaded into the hydrophobic cores of ELP micelles, but only limited drug retention times have been achieved. Herein, we report the generation of hybrid ELP/liposome nanoparticles which self-assembled rapidly in response to temperature change, encapsulated DTX at high concentrations with slow release, displayed the GRP ligand on the surface, and specifically bound to GRP receptor expressing PC-3 cells as demonstrated by flow cytometry. This novel type of drug nanocarrier was successfully used to reduce cell viability of prostate cancer cells in vitro through the specific delivery of DTX.

[1]  W. Al-Jamal,et al.  Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. , 2016, International journal of pharmaceutics.

[2]  Wei Zhang,et al.  Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide. , 2016, International journal of pharmaceutics.

[3]  M. Yarmush,et al.  Elastin‐like polypeptides: A strategic fusion partner for biologics , 2016, Biotechnology and bioengineering.

[4]  L. A. Antón Aparicio,et al.  Role of taxanes in advanced prostate cancer , 2016, Clinical and Translational Oncology.

[5]  S. Itai,et al.  Effect of Alkyl Chain Length and Unsaturation of the Phospholipid on the Physicochemical Properties of Lipid Nanoparticles. , 2015, Chemical & pharmaceutical bulletin.

[6]  W. Jiskoot,et al.  Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  J. Cha,et al.  Formulation Optimization and In Vivo Proof-of-Concept Study of Thermosensitive Liposomes Balanced by Phospholipid, Elastin-Like Polypeptide, and Cholesterol , 2014, PloS one.

[8]  Dawen Dong,et al.  Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. , 2014, Biomaterials.

[9]  Sang-Jun Park,et al.  Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes. , 2014, Colloids and surfaces. B, Biointerfaces.

[10]  Youssef W. Naguib,et al.  Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation , 2014, Molecular pharmaceutics.

[11]  J. C. Park,et al.  Dynamics and stability of lipid bilayers modulated by thermosensitive polypeptides, cholesterols, and PEGylated lipids. , 2014, Physical chemistry chemical physics : PCCP.

[12]  Aniruddha Roy,et al.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[13]  H. Cui,et al.  Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Young-sun Kim,et al.  Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[15]  J. Waxman,et al.  Current management of prostate cancer: dilemmas and trials. , 2012, The British journal of radiology.

[16]  R. Larson,et al.  Effects of the Size, Shape, and Structural Transition of Thermosensitive Polypeptides on the Stability of Lipid Bilayers and Liposomes , 2012 .

[17]  J. A. MacKay,et al.  Biodegradation of elastin‐like polypeptide nanoparticles , 2012, Protein science : a publication of the Protein Society.

[18]  Tingting Ding,et al.  Effect of Particle Size of Hydroxyapatite Nanoparticles on its Biocompatibility , 2012, IEEE Transactions on NanoBioscience.

[19]  B. Shin,et al.  Elastin-like polypeptide modified liposomes for enhancing cellular uptake into tumor cells. , 2012, Colloids and surfaces. B, Biointerfaces.

[20]  M. Carducci,et al.  Contemporary experience with ketoconazole in patients with metastatic castration‐resistant prostate cancer: Clinical factors associated with PSA response and disease progression , 2012, The Prostate.

[21]  Jeffrey M. Caves,et al.  Maleimide-thiol coupling of a bioactive peptide to an elastin-like protein polymer. , 2012, Acta biomaterialia.

[22]  S. Uzzau,et al.  Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies , 2011, Nanoscale research letters.

[23]  N. Zhang,et al.  Docetaxel-Loaded Pluronic P123 Polymeric Micelles: in Vitro and in Vivo Evaluation , 2011, International journal of molecular sciences.

[24]  A. Misra,et al.  Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology , 2010 .

[25]  D. Dearnaley,et al.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Tomohiko Ichikawa,et al.  Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. , 2008, The Journal of urology.

[28]  Jörg Huwyler,et al.  Tumor targeting using liposomal antineoplastic drugs , 2008, International journal of nanomedicine.

[29]  T. Chung,et al.  Liposomes Incorporated with Cholesterol for Drug Release Triggered by Magnetic Field , 2007 .

[30]  G. Wiederschain Protein-protein interactions. A molecular cloning manual , 2006, Biochemistry (Moscow).

[31]  A. Chilkoti,et al.  Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[32]  L. Collette,et al.  Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.

[33]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Ashutosh Chilkoti,et al.  Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[35]  H. Kumon,et al.  Treatment of androgen‐independent prostate cancer with dexamethasone: A prospective study in stage D2 patients , 2001, International journal of urology : official journal of the Japanese Urological Association.

[36]  T. Miki,et al.  Low doses of oral dexamethasone for hormone‐refractory prostate carcinoma , 2000, Cancer.

[37]  Jerome Seidenfeld,et al.  Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer , 2000, Annals of Internal Medicine.

[38]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Teissié,et al.  Control of lipid membrane stability by cholesterol content. , 1999, Biophysical journal.

[40]  E. Small,et al.  Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma , 1997, Cancer.

[41]  J. Buckner,et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.

[42]  A. Yagoda,et al.  Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.

[43]  Sandeep Kalepu,et al.  Liposomal drug delivery system - A Comprehensive Review , 2013 .

[44]  J. S. Dua,et al.  LIPOSOME: METHODS OF PREPARATION AND APPLICATIONS , 2012 .

[45]  A. Chilkoti,et al.  18 Protein Purification by Inverse Transition Cycling , 2002 .

[46]  F. Szoka,et al.  Comparative properties and methods of preparation of lipid vesicles (liposomes). , 1980, Annual review of biophysics and bioengineering.